RPAH Medical Centre
Newtown, New South Wales, Australia
Correspondence to: David J. Barnes, MBBS, FCCP, Respiratory and Sleep Physician, RPAH Medical Centre, Suite 413, 100 Carillon Ave, Newtown, New South Wales 2042; e-mail: email@example.com
To The Editor:
Osaki and colleagues (May 1999)1have recently
reported their experience with bronchial arterial infusion (BAI) of
chemotherapy in centrally located early stage lung cancer. They report
prolonged disease-free survival in six of seven patients treated in
this manner, with one patient dying of massive hemoptysis 3 months
after BAI. While this is an interesting pilot study, there are a number
of questions raised by this report, mainly related to patient
selection. Four patients had a single carcinoma in situ
lesion (stage 0), while the remaining three patients had a carcinoma
in situ lesion in addition to a latter stage carcinoma (T2,
T3, or T4). All isolated carcinoma in situ lesions
seem to have been diagnosed on sputum cytology alone. It is not clear
in the report whether those with isolated in situ lesions
were symptomatic or whether the cytology was done as part of a
screening program for high-risk individuals. No mention is made of
bronchial biopsies, and it is therefore assumed that the diagnosis was
made on cytology alone. Most would agree that this pathologic diagnosis
is difficult to make on cytology alone and usually requires bronchial
A beneficial effect of BAI on survival cannot be assumed from
this pilot study. In the first instance, all invasive carcinomas were
managed by appropriate surgical resection. Secondly, the prognosis of
carcinoma in situ lesions of the bronchus is generally very
good. The finding of carcinoma in situ at the bronchial
margin after resection for bronchogenic carcinoma has been shown to
have no adverse effect on survival, suggesting an inherently good
prognosis for in situ lesions.3–5 Future
studies of BAI would therefore require inclusion of patients other than
those with stage 0 disease.
Patients with carcinoma in situ may not require active
therapeutic intervention, given the absence of any adverse impact on
survival when this pathology is present.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.